Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Alexander QuaasCarina HeydtDirk WaldschmidtHakan AlakusThomas ZanderTobias GoeserPhilipp KasperChristiane BrunsAnna BrunnWilfried RothNils HartmannAnne BunckMatthias SchmidtReinhard BuettnerSabine Merkelbach-BrusePublished in: BMC gastroenterology (2019)
Our results underscore, in particular, the relevance of potentially treatable molecular alterations (like ERBB2, BRCA and MSI) in small bowel carcinomas. Further studies are needed to proof the efficacy of these targeted therapies in small bowel carcinomas.